Open AccessSorafenib and Sunitinib for the Treatment of Metastatic Thyroid Cancer of Follicular Origin: A 7-Year Single-Centre Experience
Author(s) -
Francisco Sousa Santos,
Rita Santos,
Valeriano Leite
Publication year - 2019
Publication title -
european thyroid journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.23
H-Index - 10
eISSN - 2235-0802
pISSN - 2235-0640
DOI - 10.1159/000501680
Subject(s) - sorafenib , sunitinib , medicine , lenvatinib , oncology , thyroid cancer , adverse effect , refractory (planetary science) , progression free survival , cancer , chemotherapy , physics , astrobiology , hepatocellular carcinoma
Radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) is a rare form of DTC which poses a therapeutic challenge due to the scarcity of effective treatment options. In recent years several tyrosine kinase inhibitors targeting specific molecular pathways involved in its pathogenesis have been investigated, such as sorafenib, lenvatinib, and sunitinib. These appear to be associated with improved progression-free survival (PFS).